Abstract:

Objective To investigate the potential application value of microbiology rapid on-site evaluation （M-ROSE） in patients with severe pneumonia. Methods Sixty patients with severe pneumonia admitted to our hospital from February 2021 to February 2023 were randomly divided into two groups， with 30 cases in each group. The control group was given empirical antibacterial therapy， while the M-ROSE group received antibacterial therapy according to the rapid detection results. The level of interleukin 6 （IL-6） and IL-10 was detected on day 1 and 7， respectively； the level of inflammatory indicators （C-reactive protein （CRP） and white blood cell （WBC）） on day 1 and day 7 after enrollment were recorded， and the difference of fever duration， length of mechanical ventilation， length of stay in ICU， 28-day mortality between the two groups was compared. Results The expression level of IL-6， IL-10 and IL-6/IL-10 in M-ROSE group on day 7 was lower than that in experience group （P < 0.05）. The duration of fever disappearance， length of mechanical ventilation and length of stay in ICU in M-ROSE group were shorter than those in the control group （P < 0.05）. There was no significant difference in 28-day mortality between the two groups （P > 0.05）. Conclusion M-ROSE is a valuable tool for the initial assessment of etiology in patients with severe pneumonia. Its potential value is to improve symptoms and inflammation， and shorten length of mechanical ventilation and length of stay in ICU.

Key words: microbiology rapid on-site evaluation （M-ROSE）, severe pneumonia, cytokines, treatment, application value